Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria (2022)
- Authors:
- Autor USP: AGUIAR, ANNA CAROLINE CAMPOS - IFSC
- Unidade: IFSC
- DOI: 10.1021/acs.jmedchem.1c01995
- Subjects: ANTIMALÁRICOS; PLASMODIUM FALCIPARUM; PLANEJAMENTO DE FÁRMACOS; ANTIPARASITÁRIOS; MALÁRIA; BIOQUÍMICA; QUÍMICA MÉDICA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Washington, DC
- Date published: 2022
- Source:
- Título: Journal of Medicinal Chemistry
- ISSN: 0022-2623
- Volume/Número/Paginação/Ano: v. 65, n. 5, p. 3798-3813, Mar. 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
TAFT, Benjamin R. e AGUIAR, Anna Caroline Campos. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. Journal of Medicinal Chemistry, v. 65, n. 5, p. 3798-3813, 2022Tradução . . Disponível em: https://doi.org/10.1021/acs.jmedchem.1c01995. Acesso em: 29 jan. 2026. -
APA
Taft, B. R., & Aguiar, A. C. C. (2022). Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. Journal of Medicinal Chemistry, 65( 5), 3798-3813. doi:10.1021/acs.jmedchem.1c01995 -
NLM
Taft BR, Aguiar ACC. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria [Internet]. Journal of Medicinal Chemistry. 2022 ; 65( 5): 3798-3813.[citado 2026 jan. 29 ] Available from: https://doi.org/10.1021/acs.jmedchem.1c01995 -
Vancouver
Taft BR, Aguiar ACC. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria [Internet]. Journal of Medicinal Chemistry. 2022 ; 65( 5): 3798-3813.[citado 2026 jan. 29 ] Available from: https://doi.org/10.1021/acs.jmedchem.1c01995 - Challenges for the development of new drugs to treat tropical and neglected disease: the importance of cooperation between academia and industry
- Epidemiological characterization and sensitivity to traditional antimalarials of Plasmodium spp. isolates from Porto Velho, western Amazon, Brazil
- In vitro assessment for cytotoxicity screening of new antimalarial candidates
- Aryl benzimidazoles: a new lead in malaria drug discovery
- Fármacos antimaláricos
- Repositioning and characterization of 1‑(Pyridin-4-yl)pyrrolidin-2- one derivatives as plasmodium cytoplasmic prolyl-tRNA synthetase inhibitors
- Potent antimalarials with development potential identified by structure-guided computational optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series
- Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome
- Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
- Fighting Plasmodium chloroquine resistance with acetylenic chloroquine analogues
Informações sobre o DOI: 10.1021/acs.jmedchem.1c01995 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
PROD032852_3068448.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
